Chronic graft versus host disease in liver – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:11:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chronic graft versus host disease in liver – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ruxolitinib-panobinostat-and-siremadlin-for-patients-continuing-treatment-from-previous-studies/ Wed, 29 Apr 2026 14:59:37 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ruxolitinib-panobinostat-and-siremadlin-for-patients-continuing-treatment-from-previous-studies/ This clinical trial is focused on evaluating the long-term safety of treatments for patients who have previously participated in studies involving the medication ruxolitinib, either alone or in combination with other drugs. Ruxolitinib is a medication used to treat certain types of blood disorders. In this study, it may be combined with other medications such as panobinostat, siremadlin (also known as HDM201), or rineterkib. The purpose of the study is to gather information on the safety of these treatments over a longer period.

Participants in this study will continue their treatment with ruxolitinib or its combinations as they have been doing in their previous studies. The study will monitor the frequency and severity of any side effects or adverse events that occur during the treatment. This information will help researchers understand the long-term safety of these medications and their combinations.

The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. It is conducted at multiple centers, allowing for a diverse group of participants. The study aims to provide valuable data on the safety of these treatments, which can benefit future patients who may receive these medications. Participants will be assessed regularly to determine any clinical benefits they may experience from the continued treatment.

]]>